Eli Lilly announced that the Phase 3 LIBRETTO-432 trial of Retevmo (selpercatinib) significantly improved event-free survival by reducing the risk of recurrence or death by 83% compared to placebo in early-stage RET fusion-positive non-small cell lung cancer patients. This is the first proven targeted adjuvant therapy for this patient group, highlighting the need for comprehensive biomarker testing at diagnosis. The results, to be published in the New England Journal of Medicine and presented at the 2026 ASCO Annual Meeting, may change clinical practice by establishing Retevmo as a new standard of care after surgery or radiation.
Eli Lilly has become the first healthcare company to reach a $1 trillion market valuation, fueled by strong sales of its weight loss drugs like Mounjaro and Zepbound. The company reported a 55.5% revenue increase year-over-year to $19.8 billion in th...
Eli Lilly's board has declared a dividend of $1.73 per share for the third quarter of 2026, payable on September 10 to shareholders recorded by August 14. This dividend reflects the company's ongoing commitment to returning value to shareholders amid...
BioArctic has entered a research collaboration with Eli Lilly to develop a new neurodegenerative disease treatment using BioArctic's BrainTransporter technology combined with a Lilly drug candidate. BioArctic will receive $30 million upfront and coul...
The Health Care Select Sector SPDR ETF (XLV) is down about 3% year-to-date despite a 14% gain over the past year. The fund's performance hinges on drug pricing policies and key product pricing, especially from Eli Lilly, which dominates XLV with its ...
Eli Lilly reported a 55.5% revenue increase in Q1 to $19.8 billion, led by $8.66 billion from Mounjaro, and raised its full-year revenue guidance to $82-$85 billion. Despite strong fundamentals, the stock has been stuck near $1,100 due to concerns ov...
